专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20150376149A1 MULTI-FUNCTIONAL ACRYLATES 有权
标题翻译：多功能丙烯酸酯
公开(公告)号：US20150376149A1
公开(公告)日：2015-12-31
申请号：US14768217
申请日：2013-11-21
申请人： EMPIRE TECHNOLOGY DEVELOPMENT LLC
发明人： Georgius Abidal ADAM
IPC分类号： C07D251/70 , C09D167/02 , C08G63/16 , C07C69/54 , C07C233/38
CPC分类号： C07D251/70 , C07C69/54 , C07C215/50 , C07C233/38 , C07D251/54 , C08F220/30 , C08F222/1006 , C08G63/16 , C08G65/3322 , C09D5/08 , C09D167/02
摘要： Disclosed herein are derivatives of phenolic and melamine compounds, methods of making these derivatives, and methods of using them. The compounds include phenolic and melamine compounds with multi-functional acrylate groups, polyethylene glycol and amino groups. The compounds may be cured to form resins that may be used in a variety of applications, such as paints, hydrogels, polyacrylate super absorbent polymers (SAPs), adhesives, composites, sealants, fillers, fire retardants, crosslinking agents, and the like.
摘要翻译：本文公开了酚醛和三聚氰胺化合物的衍生物，制备这些衍生物的方法和使用它们的方法。这些化合物包括具有多官能丙烯酸酯基团的酚和三聚氰胺化合物，聚乙二醇和氨基。化合物可以固化以形成可用于各种应用的树脂，例如油漆，水凝胶，聚丙烯酸酯超吸收聚合物（SAP），粘合剂，复合材料，密封剂，填料，阻燃剂，交联剂等。

12. 发明申请

US20150087532A1 AFFINITY REAGENTS FOR PROTEIN PURIFICATION 有权
标题翻译：蛋白质纯化的亲和试剂
公开(公告)号：US20150087532A1
公开(公告)日：2015-03-26
申请号：US14385586
申请日：2013-03-15
申请人： Impossible Foods Inc. , The Board of Trustees of the Leland Stanford Junior University
发明人： Patrick Brown , R. Edward Watts , Pehr Harbury
IPC分类号： B01J20/281 , C07D251/54 , G01N33/68
CPC分类号： B01J20/281 , A61K31/53 , B01J20/286 , B01J20/3204 , B01J20/3212 , B01J20/3248 , B01J20/3251 , C07D251/54 , C07D251/70 , C07K1/22 , G01N33/543 , G01N33/6818
摘要： Disclosed herein are methods and compositions for purifying proteins from crude solutions.
摘要翻译：本文公开了用于从粗溶液中纯化蛋白质的方法和组合物。

13. 发明授权

US08802848B2 Melamine based mannich-compounds and a process for obtaining the same 有权
标题翻译：三聚氰胺基甘露糖化合物及其获得方法
公开(公告)号：US08802848B2
公开(公告)日：2014-08-12
申请号：US13511164
申请日：2010-11-17
申请人： René Dicke , Christoph Hahn , Martin Burger , Andreas Endesfelder , Katarina Rot , Clemens Schwarzinger , Klaus Bretterbauer , Heinrich Trischler , Harald Schmidt
发明人： René Dicke , Christoph Hahn , Martin Burger , Andreas Endesfelder , Katarina Rot , Clemens Schwarzinger , Klaus Bretterbauer , Heinrich Trischler , Harald Schmidt
IPC分类号： C07D251/64 , C07D251/70 , C08G12/32
CPC分类号： C07D251/64 , C07D251/70 , C08G12/32
摘要： The present invention relates to Melamine based Mannich compounds of the general formulae (1)-(12) and a process for synthesizing melamine based Mannich-products comprising the steps of a) reacting at least one substituted melamine with at least one aldehyde, in particular formaldehyde, under basic conditions to form at least one OH-containing compound, b) reacting the at least one OH-containing compound in the presence of a catalyst to form at least one mannich-base, c1) reacting the at least one mannich-base with at least one enol-forming carbonyl compound, or c2) reacting the at least one mannich-base with at least one aromatic compound, and d) working up the reaction mixture. The invention relates further to precondensates obtainable from these products.
摘要翻译：本发明涉及通式（1） - （12）的三聚氰胺基曼尼希化合物和合成三聚氰胺的曼尼希产物的方法，包括以下步骤：a）使至少一种取代的三聚氰胺与至少一种醛反应，特别是甲醛，在碱性条件下形成至少一种含OH化合物，b）在催化剂存在下使所述至少一种含OH化合物反应以形成至少一种甘露糖基，c1）使所述至少一种甘露醇 - 与至少一种烯醇形成羰基化合物反应，或c2）使至少一种甘露糖基与至少一种芳族化合物反应，和d）处理反应混合物。本发明还涉及可从这些产品获得的预缩合物。

14. 发明授权

US08796449B2 s-Triazine compounds, pharmaceutical compositions and methods of using the same 有权
标题翻译： s-三嗪化合物，药物组合物及其使用方法
公开(公告)号：US08796449B2
公开(公告)日：2014-08-05
申请号：US13049988
申请日：2011-03-17
申请人： Neville Robert Kallenbach
发明人： Neville Robert Kallenbach
IPC分类号： C07D251/70 , C07D403/12 , C07D403/14 , A61K31/53 , A61P31/04
CPC分类号： C07D251/54 , A61K31/53 , C07D251/70 , C07D403/12 , C07D403/14 , Y02A50/473
摘要： Novel s-triazine compounds are disclosed that have a formula represented by the following: L1, L2, L3, R1, R2, R3, R4, R5a, R5b, and R5c are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, where microbial infection is either a direct cause or a related condition.
摘要翻译：公开了具有下列表示的式的新型三嗪化合物：L1，L2，L3，R1，R2，R3，R4，R5a，R5b和R5c如本文所述。化合物可以制备成药物组合物，并且可以用于预防和治疗包括人在内的哺乳动物中的多种病症，其中微生物感染是直接原因或相关病症。

15. 发明授权

US08512755B2 Compact multifunctional ligand to enhance colloidal stability of nanoparticles 有权
标题翻译：紧凑的多功能配体，增强纳米粒子的胶体稳定性
公开(公告)号：US08512755B2
公开(公告)日：2013-08-20
申请号：US13209974
申请日：2011-08-15
申请人： Igor L. Medintz , Kimihiro Susumu , Michael H. Stewart
发明人： Igor L. Medintz , Kimihiro Susumu , Michael H. Stewart
IPC分类号： C07D339/04 , C07D293/00 , C07D285/16 , C07D487/00 , A61K9/14
CPC分类号： G01N33/5005 , A61K9/14 , B82Y5/00 , B82Y15/00 , C07D251/70 , C07D295/13 , C07D339/04 , C07D409/12 , C07K17/14 , Y10S977/774 , Y10S977/788
摘要： A ligand design allows compact nanoparticle materials, such as quantum dots (QDs), with excellent colloidal stability over a wide range of pH and under high salt concentrations. Self-assembled biomolecular conjugates with QDs can be obtained which are stable in biological environments. Energy transfer with these ligands is maximized by minimizing distances between QDs/nanoparticles and donors/acceptors directly attached to the ligands or assembled on their surfaces.
摘要翻译：配体设计允许紧凑的纳米颗粒材料，例如量子点（QD），在宽的pH范围和高盐浓度下具有优异的胶体稳定性。可以获得在生物环境中稳定的与量子点的自组装生物分子缀合物。通过最小化直接连接到配体上或组装在其表面上的量子点/纳米颗粒和供体/受体之间的距离来最大化与这些配体的能量转移。

16. 发明授权

US08444879B2 Triazine derivatives 有权
标题翻译：三嗪衍生物
公开(公告)号：US08444879B2
公开(公告)日：2013-05-21
申请号：US12227042
申请日：2007-05-02
申请人： Thomas Ehlis , Elek Borsos
发明人： Thomas Ehlis , Elek Borsos
IPC分类号： C07D251/52 , C07D251/70 , C07D403/12 , C07D403/14 , A61Q17/04 , A61K8/49
CPC分类号： C07D251/52 , C07D251/70
摘要： Disclosed are triazine derivatives of formula wherein X1 is a bivalent radical of formula A and A′ independently from each other are unsubstituted or substituted, straight-chain or branched C1-C12alkylene, which is optionally interrupted by C5-C12cycloalkylene, N, O or S; C5-C12cycloalkylene; biphenylene; C6-C10arylene; or C5-C10arylene-(C1-C12alkylene); R1 is a radical of formula R2 and R3 independently from each other are hydrogen; C1-C12alkyl; OR7; NR7R8; C6-C10aryl; X2 is O, or NH; W1 is C1-C20alkyl; or a group Sp-Sil; Sp is a straight-chain or branched saturated or single or multiple unsaturated C3-C12 hydrocarbon; Sil is a silane; an oligosiloxane; or a polysiloxane moiety; and R4, R5 R6, R7, R8 and R9 independently from each other are hydrogen; C1-C12alkyl; or C3-C12cycloalkyl.
摘要翻译：公开了下式的三嗪衍生物其中X1是式A的二价基团，A'彼此独立地是未取代或取代的直链或支链C 1 -C 12亚烷基，其任选地被C 5 -C 12亚环烷基，N，O或S ; C5-C12环亚烷基; 联苯; C6-C10亚芳基或C 5 -C 10亚芳基 - （C 1 -C 12亚烷基）; R1是式R2和R3的基团彼此独立地是氢; C 1 -C 12烷基; OR7; NR7R8; C6-C10芳基; X2是O或NH; W1是C1-C20烷基; 或一组Sp-Sil; Sp是直链或支链饱和或单或多不饱和C 3 -C 12烃; 硅是硅烷; 低聚硅氧烷或聚硅氧烷部分; R 4，R 5，R 6，R 7，R 8和R 9彼此独立地为氢; C 1 -C 12烷基; 或C 3 -C 12环烷基。

17. 发明申请

US20130096100A1 DI(ARYLAMINO)ARYL COMPOUND 审中-公开
标题翻译： DI（ARYLAMINO）ARYL化合物
公开(公告)号：US20130096100A1
公开(公告)日：2013-04-18
申请号：US13618732
申请日：2012-09-14
申请人： Yutaka KONDOH , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
发明人： Yutaka KONDOH , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
IPC分类号： A61K31/551 , A61K31/541 , A61K31/53 , A61K31/517 , A61K31/5377
CPC分类号： A61K31/551 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K31/541 , C07D239/95 , C07D251/18 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/70 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12 , C07D471/10 , C07D487/08 , C07D491/113 , C07D498/10
摘要： The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins.As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.
摘要翻译：本发明提供了可用作抑制EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性的化合物。作为对具有对EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性具有抑制作用的化合物的广泛和深入研究的结果，本发明的发明人已经发现本发明的二（芳基氨基）芳基化合物具有对EML4-ALK融合蛋白和突变型EGFR蛋白激酶活性的抑制活性。这一发现导致了本发明的完成。本发明的化合物可以用作预防和/或治疗癌症，肺癌，非小细胞肺癌，小细胞肺癌，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸的药物组合物，阳性癌症，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性肺癌或EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性非小细胞肺癌等。

18. 发明申请

US20130023629A1 TRIAZINE DERIVATIVES AND APPLICATION THEREOF 有权
标题翻译： TRIAZINE衍生物及其应用
公开(公告)号：US20130023629A1
公开(公告)日：2013-01-24
申请号：US13579376
申请日：2011-02-03
申请人： Mabuko Yamaura , Yukio Orikasa , Kazuya Senzaki , Takashi Kagawa
发明人： Mabuko Yamaura , Yukio Orikasa , Kazuya Senzaki , Takashi Kagawa
IPC分类号： C07D251/24 , C08F8/32 , C08F118/08 , C08F114/22
CPC分类号： C07D251/46 , C07D251/26 , C07D251/30 , C07D251/40 , C07D251/52 , C07D251/70 , C08C19/22 , C08C19/28 , C08F2810/20 , C08K5/0025 , C08K5/3492 , C08L23/0853 , C08L2312/00
摘要： The object of the present invention is to provide a novel triazine derivative which is excellent in the heat resistance and rapid in the cross-linking rate, and can be suitably used as a crosslinking agent.The present invention relates to a triazine derivative represented by the general formula (I). (In the formula (I), Y and X are each independently, represents a diallylamino group, mono-allylamino group, allyloxy group or methallyloxy group; and Z represents an allyloxy group or methallyloxy group)
摘要翻译：本发明的目的是提供耐热性优异，交联速度快的新型三嗪衍生物，可以适合用作交联剂。本发明涉及由通式（I）表示的三嗪衍生物。（式（I）中，Y和X分别独立地表示二烯丙基氨基，单烯丙基氨基，烯丙氧基或甲代烯丙氧基; Z表示烯丙氧基或甲代烯丙氧基）

19. 发明申请

US20130011637A1 WATER-SOLUBLE AZO COMPOUND OR SALT THEREOF, INK COMPOSITION, AND COLORED BODY 有权
标题翻译：水溶性AZO化合物或其盐，墨水组合物和有色体
公开(公告)号：US20130011637A1
公开(公告)日：2013-01-10
申请号：US13634798
申请日：2011-03-24
申请人： Ryoutarou Morita , Noriko Kajiura
发明人： Ryoutarou Morita , Noriko Kajiura
IPC分类号： C09B33/12 , B32B3/10 , C09D11/02 , B41J2/015 , B41J2/17
CPC分类号： C09B43/16 , C07D251/70 , C09B29/0803 , C09B33/02 , C09B33/12 , C09B62/09 , C09D11/322 , C09D11/328 , Y10T428/24802
摘要： A water-soluble azo compound represented by formula (1) or a salt thereof, and an ink composition containing the compound or salt. The ink composition has a chroma saturation and hue suitable for inkjet recording, and enables a material recorded therewith to have high fastness in various fields, in particular high ozone gas resistance, while enabling an image recorded therewith to have excellent storage stability and the like. In formula (1), Q represents a halogen atom; x represents an integer of 2 to 4; and the group A represents an amino group represented by the following formula (101). In formula (101), y represents an integer of 1 to 3.
摘要翻译：由式（1）表示的水溶性偶氮化合物或其盐，以及含有该化合物或盐的油墨组合物。油墨组合物具有适于喷墨记录的色度饱和度和色调，并且使得记录在其中的材料在各种领域中具有高坚牢度，特别是高耐臭氧气体阻力，同时能够使其记录的图像具有优异的储存稳定性等。在式（1）中，Q表示卤原子; x表示2〜4的整数， A为由下式（101）表示的氨基。在式（101）中，y表示1〜3的整数。

20. 发明授权

US08318702B2 Di(arylamino)aryl compounds 有权
标题翻译：二（芳基氨基）芳基化合物
公开(公告)号：US08318702B2
公开(公告)日：2012-11-27
申请号：US12448759
申请日：2008-07-04
申请人： Yutaka Kondoh , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
发明人： Yutaka Kondoh , Kazuhiko Iikubo , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani , Itsuro Shimada , Takahiro Matsuya , Kazuo Kurosawa , Akio Kamikawa , Hiroyuki Mano
IPC分类号： A01N57/00 , A01N43/00 , A01N43/66 , A61K31/675 , A61K31/00 , A61K31/53 , C07D251/00 , C07D253/00 , C07D251/40 , C07D251/18 , C07D251/48
CPC分类号： A61K31/551 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K31/541 , C07D239/95 , C07D251/18 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/70 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12 , C07D471/10 , C07D487/08 , C07D491/113 , C07D498/10
摘要： The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins.As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.
摘要翻译：本发明提供了可用作抑制EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性的化合物。作为对具有对EML4-ALK融合蛋白和突变型EGFR蛋白的激酶活性具有抑制作用的化合物的广泛和深入研究的结果，本发明的发明人已经发现本发明的二（芳基氨基）芳基化合物具有对EML4-ALK融合蛋白和突变型EGFR蛋白激酶活性的抑制活性。这一发现导致了本发明的完成。本发明的化合物可以用作预防和/或治疗癌症，肺癌，非小细胞肺癌，小细胞肺癌，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸的药物组合物，阳性癌症，EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性肺癌或EML4-ALK融合多核苷酸阳性和/或突变型EGFR多核苷酸阳性非小细胞肺癌等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式